Develops genetic tests for cancer and prenatal health.
Jun 2026Revenue $807M/yrExpenses $905M/yr
Fell below break-even Jul 2019
Figures by year
When will Myriad Genetics be profitable again?
Its expenses passed its revenue in Jul 2019. In the 12 months to Jun 2026, revenue was $807M and expenses $905M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $825M | $1.21B | −$387M |
| Dec 2024 | $838M | $961M | −$124M |
| Dec 2023 | $753M | $1.01B | −$257M |
| Dec 2022 | $678M | $819M | −$141M |
| Dec 2021 | $691M | $881M | −$191M |
| Dec 2020 | $557M | $847M | −$290M |
| Jun 2020 | $639M | $870M | −$232M |
| Jun 2019 | $851M | $844M | $7.60M |
| Jun 2018 | $744M | $622M | $122M |
| Jun 2017 | $729M | $685M | $44.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.